BE2014C077I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C077I2
BE2014C077I2 BE2014C077C BE2014C077C BE2014C077I2 BE 2014C077 I2 BE2014C077 I2 BE 2014C077I2 BE 2014C077 C BE2014C077 C BE 2014C077C BE 2014C077 C BE2014C077 C BE 2014C077C BE 2014C077 I2 BE2014C077 I2 BE 2014C077I2
Authority
BE
Belgium
Prior art keywords
factor viii
factor
promoter
vector
cell line
Prior art date
Application number
BE2014C077C
Other languages
English (en)
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/fr
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of BE2014C077I2 publication Critical patent/BE2014C077I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
BE2014C077C 2000-03-22 2014-12-29 BE2014C077I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (fr) 2000-03-22 2000-03-22 Préparation de facteurs de la coagulation sanguine recombinants en lignées cellulaires humaines
US20324900P 2000-05-08 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (fr) 2000-03-22 2001-03-21 Production de facteurs de coagulation sanguine recombines dans des lignees de cellules humaines
EP01927769A EP1266006B1 (fr) 2000-03-22 2001-03-21 Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines

Publications (1)

Publication Number Publication Date
BE2014C077I2 true BE2014C077I2 (fr) 2020-01-30

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C077C BE2014C077I2 (fr) 2000-03-22 2014-12-29

Country Status (28)

Country Link
US (1) US7572619B2 (fr)
EP (2) EP1266006B1 (fr)
JP (1) JP3894795B2 (fr)
KR (1) KR100581574B1 (fr)
CN (1) CN1454257B (fr)
AT (1) ATE312176T1 (fr)
AU (3) AU5471501A (fr)
BE (1) BE2014C077I2 (fr)
BG (1) BG65930B1 (fr)
BR (1) BRPI0109494B8 (fr)
CA (1) CA2404163C (fr)
CZ (1) CZ303929B6 (fr)
DE (1) DE60115613T2 (fr)
DK (1) DK1266006T3 (fr)
EA (1) EA004317B1 (fr)
EE (1) EE200200538A (fr)
ES (1) ES2254403T3 (fr)
FR (1) FR15C0003I2 (fr)
HR (1) HRP20020767B1 (fr)
HU (1) HU228091B1 (fr)
IL (2) IL151857A0 (fr)
MX (1) MXPA02009221A (fr)
NO (1) NO330910B1 (fr)
NZ (1) NZ521732A (fr)
RS (1) RS50743B (fr)
SI (1) SI1266006T1 (fr)
SK (1) SK287706B6 (fr)
WO (1) WO2001070968A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50743B (sr) * 2000-03-22 2010-08-31 OCTAPHARMA BIOPHARMACEUTICALS GmbH. Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
CN1205221C (zh) * 2000-09-19 2005-06-08 埃默里大学 修饰的凝血因子ⅷ
EP1469064A1 (fr) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression des protéines dans des cellules endothéliales dérivées de cellules précurseurs du sang de cordon ombilical
WO2005094873A1 (fr) 2004-03-19 2005-10-13 Baxter International Inc. Facteur ixa pour le traitement de troubles de saignement
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ATE549037T1 (de) 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8530192B2 (en) * 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
EP1707634A1 (fr) 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
EP1739179A1 (fr) 2005-06-30 2007-01-03 Octapharma AG Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines
EP2495307B9 (fr) 2006-07-13 2018-05-02 Wyeth LLC Production du factor IX de coagulation avec une glycosylation ameliorée
WO2008134665A1 (fr) * 2007-04-26 2008-11-06 Inspiration Biopharmaceuticals, Inc. Protéines dépendantes de la vitamine k recombinées à teneur élevée en acide sialique et leurs procédés de préparation
EP2198870A4 (fr) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp Activateur pour le promoteur du facteur vii de la coagulation du sang et son utilisation
WO2010020690A1 (fr) 2008-08-21 2010-02-25 Octapharma Ag Facteurs humains viii et ix produits par recombinaison génétique
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
WO2011041770A1 (fr) 2009-10-02 2011-04-07 The Children's Hospital Of Philadelphia Compositions et procédés pour renforcer la fonction du facteur de coagulation viii
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
EP2707387B1 (fr) 2011-05-13 2019-12-25 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
CA2862516C (fr) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions et methodes d'utilisation pour le traitement de troubles metaboliques
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
EP2917233A1 (fr) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Variants d'albumine
US20150352194A1 (en) * 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CA2908350C (fr) 2013-04-02 2023-08-08 Futa Mimoto Variant de region fc
EP2853538A1 (fr) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues de temporin-Sha et leurs utilisations
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
NZ730054A (en) 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CA3019425A1 (fr) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Therapie genique pour le traitement de l'hemophilie a
WO2018025982A1 (fr) 2016-08-05 2018-02-08 中外製薬株式会社 Composition pour la prophylaxie ou le traitement de maladies liées à il-8
WO2018210771A1 (fr) 2017-05-17 2018-11-22 Octapharma Ag Procédé de production d'une protéine cible recombinante
WO2020020364A1 (fr) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 Procédé de préparation d'un facteur viii de coagulation humain recombinant
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
EP4352083A1 (fr) 2021-06-11 2024-04-17 Sorbonne Universite Peptides antimicrobiens courts

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
EP0218713B1 (fr) * 1985-04-22 1992-03-25 Genetics Institute, Inc. Production a haut rendement du facteur actif ix
WO1987004187A1 (fr) * 1986-01-03 1987-07-16 Genetics Institute, Inc. PROCEDE DE PRODUCTION DE PROTEINES DE TYPE FACTEUR VIII:c
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
EP0670332A3 (fr) * 1989-11-17 1995-10-25 Novo Nordisk As Complexes de protéines présentant l'activité du facteur VIII:C, et leur production.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
HUT63459A (en) 1990-01-26 1993-08-30 Immuno Ag Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
EP0915975A2 (fr) * 1996-07-03 1999-05-19 Chiron Corporation Procedes d'administration d'excipients d'apport de genes recombines dans le traitement de l'hemophilie
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1999029848A1 (fr) * 1997-12-05 1999-06-17 The Immune Response Corporation Vecteurs et genes a expression accrue
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2362970A1 (fr) * 1999-02-19 2000-08-24 Octagene Gmbh Couples hormone-recepteur hormonal, constructions d'acides nucleiques, et utilisation de ceux-ci en therapie genique
WO2001012836A1 (fr) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Cristal de produit de recombinaison proteique tronque renfermant un domaine c2 du facteur de coagulation viii, avec ou sans ligand lie, et procedes d'utilisation
RS50743B (sr) * 2000-03-22 2010-08-31 OCTAPHARMA BIOPHARMACEUTICALS GmbH. Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
WO2003009237A1 (fr) * 2001-07-18 2003-01-30 Skaginn Hf. Dispositif et procede pour l'etablissement d'un lien entre un operateur et des informations relatives a un objet traite par cet operateur

Also Published As

Publication number Publication date
AU2001254715B2 (en) 2006-02-02
EE200200538A (et) 2004-04-15
HUP0300588A2 (hu) 2003-06-28
BG107152A (bg) 2003-06-30
DE60115613D1 (de) 2006-01-12
NO20024475D0 (no) 2002-09-19
HUP0300588A3 (en) 2005-09-28
DK1266006T3 (da) 2006-01-16
CN1454257A (zh) 2003-11-05
MXPA02009221A (es) 2005-07-25
JP2003530093A (ja) 2003-10-14
SK287706B6 (en) 2011-07-06
EP1460131A2 (fr) 2004-09-22
NO330910B1 (no) 2011-08-15
CA2404163C (fr) 2009-09-29
EA200201008A1 (ru) 2003-02-27
NZ521732A (en) 2004-05-28
RS50743B (sr) 2010-08-31
SK15042002A3 (sk) 2003-09-11
NO20024475L (no) 2002-11-20
KR100581574B1 (ko) 2006-05-22
EP1266006B1 (fr) 2005-12-07
BRPI0109494B1 (pt) 2021-05-11
EP1460131A3 (fr) 2005-06-01
AU5471501A (en) 2001-10-03
US7572619B2 (en) 2009-08-11
ES2254403T3 (es) 2006-06-16
EA004317B1 (ru) 2004-02-26
HRP20020767B1 (en) 2011-09-30
ATE312176T1 (de) 2005-12-15
JP3894795B2 (ja) 2007-03-22
WO2001070968A2 (fr) 2001-09-27
CN1454257B (zh) 2013-01-16
WO2001070968A3 (fr) 2001-12-13
BG65930B1 (bg) 2010-05-31
HU228091B1 (en) 2012-10-29
BRPI0109494B8 (pt) 2021-05-25
CZ20023166A3 (cs) 2003-02-12
AU2006201848A1 (en) 2006-05-25
YU71002A (sh) 2005-11-28
FR15C0003I2 (fr) 2015-11-20
HRP20020767A2 (en) 2005-02-28
CA2404163A1 (fr) 2001-09-27
EP1266006A2 (fr) 2002-12-18
IL151857A0 (en) 2003-04-10
CZ303929B6 (cs) 2013-07-03
US20040023333A1 (en) 2004-02-05
SI1266006T1 (sl) 2006-06-30
IL151857A (en) 2010-05-31
FR15C0003I1 (fr) 2015-02-27
KR20030011079A (ko) 2003-02-06
BR0109494A (pt) 2002-12-10
DE60115613T2 (de) 2006-08-24

Similar Documents

Publication Publication Date Title
BE2014C077I2 (fr)
EP1395293A4 (fr) Vecteurs lentiviraux codant des facteurs de coagulation utiles pour la therapie genique
EP1005376A4 (fr) Methodes et compositions utilisees en therapie genique dans le traitement de l'hemophilie
IL160897A0 (en) Human coagulation factor vii polypeptides
CA2400295A1 (fr) Facteur viii modifie
WO2003104270A3 (fr) Genes de la duduline 2, produits d'expression, modele animal non humain : utilisations dans les maladies hematologiques humaines
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
MXPA04003944A (es) Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
GB2382580B (en) Fusion protein having enhanced in vivo activity of erythropoietin
ES8607730A1 (es) Procedimiento para producir el factor viii-c humano
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
WO2002050111A3 (fr) Laminine 10 isolee
MX9701720A (es) Proceso para la fabricacion de una palidipina modificada, inhibidora de la agregacion plaquetaria inducida por colageno.
EP1634954A4 (fr) Protease, adn codant pour cette protease et procede de production de cette protease
EP1679372A4 (fr) Nouveau polypeptide plexine, adn codant pour celui-ci et utilisation de celui-ci
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки